<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370281">
  <stage>Registered</stage>
  <submitdate>5/04/2016</submitdate>
  <approvaldate>11/04/2016</approvaldate>
  <actrnumber>ACTRN12616000469415</actrnumber>
  <trial_identification>
    <studytitle>Effects of noradrenergic and antimuscarinic agents on upper airway muscle activity during sleep</studytitle>
    <scientifictitle>Effects of noradrenergic and antimuscarinic agents on upper airway muscle activity during sleep in healthy adults</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Upper airway muscle activity asleep</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Reboxetine 4mg + Hyoscine 20mg taken orally just prior to sleep (single dose)
1 week washout</interventions>
    <comparator>Placebo (sugar pill), taken orally (participants will act as their own controls in a cross-over design)</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Genioglossus muscle activity during sleep using intramuscular electromyography (EMG).</outcome>
      <timepoint>Single night acute overnight sleep studies (placebo vs. drug)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Tensor palatini muscle activity during sleep using intramuscular electromyography (EMG).</outcome>
      <timepoint>Single night acute overnight sleep studies (placebo vs. drug)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Sleep efficiency from the overnight polysomnogram</outcome>
      <timepoint>Single night acute overnight sleep studies (placebo vs. drug)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Upper airway resistance using an epiglottic pressure catheter</outcome>
      <timepoint>Single night acute overnight sleep studies (placebo vs. drug)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Minute ventilation measured using a nasal mask and pneumotachograph.</outcome>
      <timepoint>Single night acute overnight sleep studies (placebo vs. drug)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Arousal index from the overnight polysomnogram</outcome>
      <timepoint>Single night acute overnight sleep studies (placebo vs. drug)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apnoea/hypopnoea index from the overnight polysomnogram</outcome>
      <timepoint>Single night acute overnight sleep studies (placebo vs. drug)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy men and women aged 18-65 years who do not have any known sleep disorders</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-Women lactating, pregnant or of childbearing potential who are not willing to avoid becoming pregnant during the study.
-Patients with any other medical condition which may interfere in the evaluation of the study.
-Patients with a previous history of addiction to alcohol or drugs.
-Patients taking medications known to affect sleep or muscle activity.
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>14/04/2016</anticipatedstartdate>
    <actualstartdate>15/04/2016</actualstartdate>
    <anticipatedenddate>1/10/2016</anticipatedenddate>
    <actualenddate>25/07/2016</actualenddate>
    <samplesize>10</samplesize>
    <actualsamplesize>10</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/08/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Neuroscience Research Australia (NeuRA)</primarysponsorname>
    <primarysponsoraddress>Neuroscience Research Australia (NeuRA)
Barker Street,
Randwick, NSW, 2031</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NeuroSleep (NHMRC Centre of Research Excellence 1060992)</fundingname>
      <fundingaddress>National Health and Medical Research Council
GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To determine if sleep-related reductions in upper airway muscle activity during sleep will be higher after a combined noradrenergic/antimuscarinic intervention compared to placebo.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>South Eastern Sydney Local Health District Human Research Ethics Committee</ethicname>
      <ethicaddress>Room G71 East Wing
Edmund Blacket Building
Prince of Wales Hospital
Cnr High and Avoca Streets
RANDWICK, NSW 2031</ethicaddress>
      <ethicapprovaldate>30/11/2015</ethicapprovaldate>
      <hrec>15/234 (HREC/15/POWH/449)</hrec>
      <ethicsubmitdate>27/08/2015</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia (NeuRA)
PO Box 1165
Randwick, NSW, 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Mr</title>
      <name>Benjamin Tong</name>
      <address>Neuroscience Research Australia (NeuRA)
PO Box 1165
Randwick, NSW, 2031</address>
      <phone>+61 2 9399Â 1886</phone>
      <fax />
      <email>b.tong@neura.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia (NeuRA)
PO Box 1165
Randwick, NSW, 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Danny Eckert</name>
      <address>Neuroscience Research Australia (NeuRA)
PO Box 1165
Randwick, NSW, 2031</address>
      <phone>+61 2 9399 1814</phone>
      <fax />
      <email>d.eckert@neura.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>